TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) CEO Mary Szela purchased 39,682 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the purchase, the chief executive officer directly owned 1,065,215 shares of the company’s stock, valued at approximately $2,758,906.85. This represents a 3.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
TriSalus Life Sciences Stock Performance
TLSI traded up $0.35 during trading on Monday, reaching $3.03. 773,435 shares of the company’s stock were exchanged, compared to its average volume of 276,402. TriSalus Life Sciences, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58. The business has a 50 day moving average price of $4.18 and a 200 day moving average price of $5.13. The company has a market capitalization of $185.77 million, a P/E ratio of -2.15 and a beta of 0.56.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. As a group, analysts predict that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on TLSI
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in TLSI. First Light Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the first quarter valued at about $20,267,000. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter worth about $10,900,000. Wasatch Advisors LP bought a new stake in TriSalus Life Sciences during the 1st quarter worth about $5,752,000. Vanguard Group Inc. raised its holdings in TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its holdings in TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after purchasing an additional 265,618 shares during the last quarter. 2.58% of the stock is owned by institutional investors.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
